Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.55 |
| ▸ | SOS1 | Q07889 | 7/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838748 | 0.86 | SLC6A4 (0.75) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL5836402 | 0.84 | HTR2A (0.48) | HTR2ASLC6A4KCNH2SOS1EPAS1 | |
| SCHEMBL6800908 | 0.84 | SLC6A4 (0.59) | HTR2ASLC6A4KCNH2SOS1EPAS1 | |
| SCHEMBL5836407 | 0.78 | HTR2A (0.67) | HTR2ASLC6A4KCNH2EPAS1CYP2D6 | |
| SCHEMBL5836497 | 0.73 | HTR2A (0.68) | HTR2ASLC6A4KCNH2SOS1SLC6A2 | |
| SCHEMBL2629466 | 0.73 | HTR7 (0.46) | — | |
| SCHEMBL5837060 | 0.72 | SLC6A4 (0.67) | HTR2ASLC6A4KCNH2SOS1EPAS1 | |
| SCHEMBL5836991 | 0.72 | HTR2A (0.80) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL9119793 | 0.71 | HTR2A (0.66) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL10834476 | 0.71 | HRH3 (0.49) | HTR2ASLC6A4KCNH2EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165217-A1 | Combination treatment for anxiety and depression | PFIZER INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165217-A1 | Combination treatment for anxiety and depression | GABRA1, GABRA2, GABRA5 | HTR2A 48/4885SLC6A4 40/4885KCNH2 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.